Prosensa Holding N.V. announces clos­ing of Initial Public Offering

Leiden, the Netherlands—July 8, 2013—Prosensa Holding N.V. (“Prosensa”) announced today the clos­ing of its pre­vi­ous­ly announced ini­tial pub­lic offer­ing of 6,900,000 of its ordi­nary shares at a price of $13.00 per share (includ­ing an addi­tion­al 900,000 ordi­nary shares pur­suant to the exer­cise of the over-allot­ment option by the under­writ­ers). The ordi­nary shares began trad­ing on the Nasdaq Global Market on June 28, 2013 under the sym­bol “RNA”.
Prosensa intends to use the pro­ceeds from the offer­ing to fund its cur­rent DMD devel­op­ment port­fo­lio, its ear­ly-stage DMD dis­cov­ery work and DMD-sup­port projects, to fund oth­er non-DMD projects and for work­ing cap­i­tal and gen­er­al cor­po­rate pur­pos­es.
J.P. Morgan and Citigroup act­ed as joint book-run­ning man­agers for the offer­ing. Leerink Swann act­ed as lead man­ag­er, and Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital act­ed as co-man­agers.
A reg­is­tra­tion state­ment relat­ing to this offer­ing was declared effec­tive by the Securities and Exchange Commission on June 27, 2013. This press release shall not con­sti­tute an offer to sell or a solic­i­ta­tion of an offer to buy, nor shall there be any sale of these secu­ri­ties in any state or juris­dic­tion in which such offer, solic­i­ta­tion or sale would be unlaw­ful, pri­or to reg­is­tra­tion or qual­i­fi­ca­tion under the secu­ri­ties laws of any such state or juris­dic­tion.
The offer­ing will be made only by means of a prospec­tus. A copy of the pre­lim­i­nary prospec­tus relat­ing to the offer­ing may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; tele­phone: 866-803-9204 or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, tele­phone: 800-831-9146, email:

Leave a Reply

Your email address will not be published. Required fields are marked *